Rothschild Asset Management Inc. purchased a new position in Baxter International Inc. (NYSE:BAX) during the first quarter, Holdings Channel reports. The fund purchased 8,277 shares of the medical instruments supplier’s stock, valued at approximately $429,000.
Several other institutional investors have also added to or reduced their stakes in the company. Reilly Financial Advisors LLC boosted its position in Baxter International by 20.4% in the first quarter. Reilly Financial Advisors LLC now owns 2,054 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 348 shares in the last quarter. Quadrant Capital Group LLC raised its position in Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock valued at $113,000 after buying an additional 31 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its position in Baxter International by 6.1% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 2,533 shares of the medical instruments supplier’s stock valued at $131,000 after buying an additional 145 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Baxter International by 3.9% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,776 shares of the medical instruments supplier’s stock valued at $144,000 after buying an additional 103 shares during the last quarter. Finally, Trust Co. of Vermont raised its position in Baxter International by 8.7% in the first quarter. Trust Co. of Vermont now owns 3,282 shares of the medical instruments supplier’s stock valued at $170,000 after buying an additional 262 shares during the last quarter. Institutional investors and hedge funds own 83.90% of the company’s stock.
Shares of Baxter International Inc. (NYSE BAX) opened at 60.72 on Monday. The firm has a market cap of $33.01 billion, a price-to-earnings ratio of 17.97 and a beta of 0.66. The stock’s 50 day moving average price is $58.81 and its 200 day moving average price is $52.10. Baxter International Inc. has a 12 month low of $43.13 and a 12 month high of $61.52.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, April 26th. The medical instruments supplier reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.07. Baxter International had a return on equity of 14.03% and a net margin of 18.09%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter in the previous year, the firm posted $0.36 earnings per share. The company’s revenue was up 4.2% compared to the same quarter last year. Equities research analysts predict that Baxter International Inc. will post $2.27 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, July 3rd. Investors of record on Friday, June 2nd were paid a $0.16 dividend. This is a boost from Baxter International’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend was Wednesday, May 31st. This represents a $0.64 annualized dividend and a dividend yield of 1.05%. Baxter International’s payout ratio is 19.05%.
WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/markets/2284622/rothschild-asset-management-inc-acquires-new-position-in-baxter-international-inc-bax.html.
Several research firms recently issued reports on BAX. Royal Bank of Canada increased their target price on Baxter International from $55.00 to $58.00 and gave the stock a “sector perform” rating in a research note on Thursday, April 27th. BMO Capital Markets reaffirmed a “hold” rating and issued a $55.00 price target on shares of Baxter International in a research report on Thursday, April 27th. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Cantor Fitzgerald began coverage on Baxter International in a research report on Thursday, June 29th. They issued an “overweight” rating and a $70.00 price target on the stock. Finally, Barclays PLC increased their price target on Baxter International from $62.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Baxter International presently has an average rating of “Buy” and an average target price of $60.33.
In related news, SVP Brik V. Eyre sold 130,732 shares of the business’s stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $55.69, for a total value of $7,280,465.08. Following the transaction, the senior vice president now owns 49,966 shares in the company, valued at $2,782,606.54. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Carole J. Shapazian sold 2,618 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $57.92, for a total value of $151,634.56. Following the completion of the transaction, the director now owns 9,848 shares in the company, valued at approximately $570,396.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 137,110 shares of company stock worth $7,642,246. Insiders own 0.05% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284622/rothschild-asset-management-inc-acquires-new-position-in-baxter-international-inc-bax.html
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.